C/O ADMA BIOLOGICS, INC., RAMSEY, NJ
Material Contracts, End of Material Contract, Financial Results, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Shareholder votes
Announces First Quarter 2025 Financial Results and Provides Business Update
Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Annual Report to Security Holders
Earnings Release
News
Investor Presentation
Q2
Q1
Notice of Late Filing for Annual Report
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Certification of Termination of Registration of a Class of Security
Registration of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
S-8 POS